Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer.

Autor: Kohli M; Department of Medical Oncology, Mayo Clinic, Rochester, MN. Electronic address: Manish.Kohli@moffitt.org., Oberg AL; Department of Health Sciences Research, Mayo Clinic, Rochester, MN., Mahoney DW; Department of Health Sciences Research, Mayo Clinic, Rochester, MN., Riska SM; Department of Health Sciences Research, Mayo Clinic, Rochester, MN., Sherwood R; Institute for Biotechnology and Life Science Technologies, Cornell University, Ithaca, NY., Zhang Y; Department of Health Sciences Research, Mayo Clinic, Rochester, MN., Zenka RM; Proteomcis Core, Mayo Clinic, Rochester, MN., Sahasrabudhe D; Department of Medicine, University of Rochester, NY., Qin R; Clinical Biostatistics, Janssen Pharmaceuticals, Raritan, NJ., Zhang S; Institute for Biotechnology and Life Science Technologies, Cornell University, Ithaca, NY. Electronic address: sz14@cornell.edu.
Jazyk: angličtina
Zdroj: Clinical genitourinary cancer [Clin Genitourin Cancer] 2019 Aug; Vol. 17 (4), pp. 248-253.e7. Date of Electronic Publication: 2019 Mar 15.
DOI: 10.1016/j.clgc.2019.03.006
Abstrakt: Background: We investigated the serum proteome of hormone-sensitive prostate cancer patients to determine candidate biomarkers associated with androgen deprivation therapy (ADT) efficacy.
Patients and Methods: Serum proteomes generated using isobaric mass tags for relative and absolute quantitation were analyzed using reverse-phase liquid chromatography coupled to tandem mass spectrometry. The advanced hormone-sensitive prostate cancer cohorts studied were: (1) untreated "paired" pre-ADT and 4-month post-ADT hormone-sensitive patients (n = 15); (2) "early ADT failure" patients (n = 10) in whom ADT treatment failed within a short period of time; and (3) "late ADT failure" patients (n = 10) in whom ADT treatment failed after a prolonged response time. Differential abundance was assessed, and ingenuity pathway analysis (IPA) was used to identify interaction networks in selected candidates from these comparisons.
Results: Between "post-ADT" and combined "early" and "late" ADT failure groups 149 differentially detected candidates were observed, and between "early" and "late" ADT failure groups 98 candidates were observed; 47 candidates were common in both comparisons. IPA network enrichment analysis of the 47 candidates identified 3 interaction networks (P < .01) including 17-β-estradiol, nuclear factor kappa-light-chain enhancer of activated B cells complex, and P38 mitogen-activated protein kinases as pathways with potential markers of response to ADT.
Conclusion: A global proteomic analysis identified pathways with markers of ADT response, which will need validation in independent data sets.
(Copyright © 2019 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: